Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Jun 2017
At a glance
- Drugs OPA 15406 (Primary)
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Medimetriks Pharmaceuticals
- 20 Jun 2017 Planned End Date changed from 1 Apr 2017 to 1 Jul 2017.
- 20 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Apr 2017.